Radiotherapy is an important modality used for the treatment of lung cancer. Seventy‐seven
percent of all patients with lung cancer have an evidence‐based indication for radiotherapy …

Progress in the overall treatment of small-cell lung cancer (SCLC) has moved at a slower
pace than non–small-cell lung cancer. In fact, the standard treatment regimen for limited …

Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer. Although SCLC is
characterised by rapid responses to chemotherapy (ChT) and sensitivity to radiotherapy …

Purpose Several sentinel phase III randomized trials have recently been published
challenging traditional radiation therapy (RT) practices for small cell lung cancer (SCLC) …

Background Concurrent chemoradiotherapy is the standard of care in limited-stage small-
cell lung cancer, but the optimal radiotherapy schedule and dose remains controversial. The …

Radiotherapy (RT) plays a major role in the curative treatment of locally advanced non-small
cell lung cancer (NSCLC). Therefore, the ACROP committee was asked by the ESTRO to …

Small cell lung cancer (SCLC), as a proportion, makes up only 15–17% of lung cancer
cases. The development of treatments for SCLC has remained stagnant for decades, and …

Small cell lung cancer (SCLC) comprises about 15% of all lung cancers. It is an aggressive
disease, with early metastasis and a poor prognosis. Until recently, SCLC treatment …

DNA-damaging agents exploit increased genomic instability, a hallmark of cancer. Recently,
inhibitors targeting the DNA damage response (DDR) pathways, such as PARP inhibitors …

Small-cell lung cancer (SCLC) accounts for 15% of lung cancers. Only one-third of patients
are diagnosed at limited stage. The median survival remains to be around 15–20 months …